UK markets open in 3 hours 55 minutes
  • NIKKEI 225

    28,469.15
    +185.23 (+0.65%)
     
  • HANG SENG

    23,585.40
    -266.84 (-1.12%)
     
  • CRUDE OIL

    70.68
    +0.73 (+1.04%)
     
  • GOLD FUTURES

    1,790.40
    +5.20 (+0.29%)
     
  • DOW

    35,135.94
    +236.60 (+0.68%)
     
  • BTC-GBP

    42,868.69
    -505.73 (-1.17%)
     
  • CMC Crypto 200

    1,440.39
    +11.45 (+0.80%)
     
  • ^IXIC

    15,782.83
    +291.18 (+1.88%)
     
  • ^FTAS

    4,057.63
    +37.25 (+0.93%)
     

Plaque Psoriasis Epidemiology Forecast Report 2021-2030: Focus on US, Japan, France, Germany, Italy, Spain, and the UK - ResearchAndMarkets.com

·3-min read

DUBLIN, October 19, 2021--(BUSINESS WIRE)--The "Plaque Psoriasis - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Plaque psoriasis is the most common form of psoriasis, affecting between 80% and 90% of individuals living with psoriasis, and can occur on any area of the body such as the scalp, hands, and feet (National Psoriasis Foundation, 2018).

The publisher epidemiologists relied on the most robust country-specific data for each segmentation covered in this forecast, obtained from scientific studies published in peer-reviewed academic journals, international healthcare agency publications, nationwide neonatal registries, and national disease surveillance agencies available at the time of publication.

This report includes a 10-year forecast for the lifetime diagnosed prevalent cases of plaque psoriasis from 2020-2030. The prevalent cases of plaque psoriasis are further segmented by sex and age. Plaque psoriasis data are further segmented by severity (mild, moderate, and severe) and plaque psoriasis cases with psoriatic arthritis.

In the 7MM, the lifetime diagnosed prevalent cases of plaque psoriasis will increase from 15,726,350 in 2020 to 16,856,548 in 2030, at an Annual Growth Rate (AGR) of 0.72% per year. Similarly, lifetime diagnosed prevalent cases of psoriasis in the 5EU (France, Germany, Italy, Spain, and the UK) will increase at an AGR of 0.55%, from 7,779,141 in 2020 to 8,210,874 in 2030.

When examining the AGR by individual markets, The publisher estimates that the US will have the highest number of plaque psoriasis cases in 2030, with 8,171,859 cases at an AGR of 0.93%. Conversely, Japan will have the least number of cases by 2030, with 473,815 cases at an AGR of 0.08%.

Scope

  • The plaque psoriasis epidemiology report provides an overview of the risk factors, comorbidities, and global and historical trends for plaque psoriasis in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan).

  • The report includes a 10-year epidemiological forecast for the lifetime diagnosed prevalent cases of plaque psoriasis segmented by sex and age (0-17 years, 18-29 years, and by 10-year age groups for age 30 years up to 80 years and older) in these markets. The lifetime diagnosed prevalent cases are further segmented by severity and plaque psoriasis cases with psoriatic arthritis in the adult population.

  • The plaque psoriasis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in plaque psoriasis.

Key Topics Covered:

1 Plaque Psoriasis: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.1.1 Risk Factors and Comorbidities

2.2 Global and Historical Trends

2.3 Forecast Methodology

2.3.1 Sources

2.3.2 Forecast Assumptions and Methods

2.4 Epidemiological Forecast for Plaque Psoriasis (2020-2030)

2.4.1 Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis

2.4.2 Age-Specific Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis

2.4.3 Sex-Specific Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis

2.4.4 Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis by Severity in the Adult Population

2.4.5 Lifetime Diagnosed Prevalent Cases of Plaque Psoriasis with PsA in the Adult Population

2.5 Discussion

2.5.1 Epidemiological Forecast Insight

2.5.2 COVID-19 Impact

2.5.3 Limitations of the Analysis

2.5.4 Strengths of the Analysis

3 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/7qmzgq

View source version on businesswire.com: https://www.businesswire.com/news/home/20211019006006/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting